Complement Therapeutics Company
.jpg)
Complement Therapeutics is a research and experimental development on biotechnology. It develops a portfolio of treatments for Complement-related diseases, including age-related macular degeneration, each with a high clinical need. Through the research program, they have gained new insights into the ways the Complement System works and how it is dysregulated in age-related macular degeneration. They also develop protein and gene therapies, multiple platforms. The company's pipeline includes perspective medicines against Geographic atrophy ('dry' age-related macular degeneration), kidney diseases, systemic diseases (lupus, ischemic reperfusion injury, Paroxysmal nocturnal hemoglobinuria), inflammation regulation of the brain.
Industry:
Geroscience
Headquarters:
Manchester, United Kingdom
Founded Date:
2020
Employees Number:
11-50
Estimated Revenue:
£780 000-7 800 000
Register and Claim Ownership